Parabilis reveals IPO plans the day after Regeneron deal as listings heat upnews2026-05-20T10:40:54+00:00May 20th, 2026|Endpoints News|
GHO Capital, CBC Group to merge, forming what could be the largest healthcare specialist investornews2026-05-20T10:22:22+00:00May 20th, 2026|Endpoints News|
Another Paragon offshoot chooses reverse merger, this time for migraine drugsnews2026-05-19T18:56:01+00:00May 19th, 2026|Endpoints News|
Regeneron reaches $125M Parabilis deal for hard-to-catch drug targetsnews2026-05-18T15:33:27+00:00May 18th, 2026|Endpoints News|
Biopharma M&A maintains strength even as large deals wanenews2026-05-15T17:56:32+00:00May 15th, 2026|Endpoints News|
M&A isn’t just for big pharma. Mid-size companies are stepping up deal huntsnews2026-05-15T12:43:17+00:00May 15th, 2026|Endpoints News|
Pfizer and Arvinas give disappointing breast cancer drug to Rigelnews2026-05-12T15:00:49+00:00May 12th, 2026|Endpoints News|
Bayer to make ‘careful but aggressive’ return to pharma M&A, CEO saysnews2026-05-12T14:06:30+00:00May 12th, 2026|Endpoints News|
Bristol Myers joins Hengrui party in 13-asset deal worth up to $15.2Bnews2026-05-12T09:06:30+00:00May 12th, 2026|Endpoints News|
Angelini fortifies neurology portfolio with $4.1B buyout of Catalystnews2026-05-07T10:40:10+00:00May 7th, 2026|Endpoints News|
